Antibody response to influenza vaccination in healthy adults

Viral Immunology

Volumn 17, Issue 4, 2004, Pages 609-615

  Brydak, Lidia B ^b   Tadeusz, Skwarczyñski ^a   Magdalena, Machaka ^c  

^a Agencja Bezpieczenstwa Wewnetrznego Warszawa   (Poland)

^b NATIONAL INSTITUTE OF HYGIENE   (Poland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEMAGGLUTININ; HEMAGGLUTININ ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE; SIALIDASE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS; DRUG CONTROL; DRUG RESPONSE; ENZYME INHIBITION; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMORAL IMMUNITY; INFLUENZA VACCINATION; LABORATORY TEST; NEURAMINIDASE INHIBITION TEST; NORMAL HUMAN; VACCINATION;

CHIRON;

EID: 11244300707     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2004.17.609     Document Type: Article

References (38)

1. Ada, G.L., and P.D. Jones. 1986. The immune response to influenza infection. Curr. Topics Microbiol. Immunol. 128:1-54.
2. Aymard-Henry, M., M.T. Coleman, W.R. Dowdle, et al. 1973. Influenza virus neuraminidase and neuraminidase inhibition test procedures. Bull. WHO 48:199-202.
3. Beran, J., R. Prymula, R. Chlibek, et al. 1998. Evaluation of reactogenicity and immunogenicity of two influenza vaccines (Vaxigrip and Fluarix) in the season 1996-1997. Centr. Eur. J. Publ. Health 4:269-273.
4. Bridges, C.B., W.W. Thompson, M.I. Meltzer, et al. 2000. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284:1655-1663.
5. Brydak, L.B. 1998. Influenza and Its Prophylaxis, 1st ed. Springer PWN, Warsaw.
6. Brydak, L.B., J. Guzy, J. Starzyk, et al. 2001. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 9:65-68.
7. Brydak, L.B., M. Machala, P. Laguna, et al. 2004. Antibody response to influenza vaccination in splenectomized patients in Poland. J. Clin. Immunol 24:225-236.
8. Brydak, L.B., M. Machala, J. Myśliwska, et al. 2003. Immune response to influenza vaccination in an elderly population. J. Clin. Immunol 23:214-222.
9. Brydak L.B., T. Rajkowski, M. Machala, et al. 1998. Humoral antibody response following influenza vaccination in patients with nephrotic syndrome. Antiinfect. Drugs Chemother. 16:151-155.
10. Brydak L.B., R. Rokicka-Milewska, M. Machala, et al. 1998. Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukemia. Pediatr. Infect. Dis. J. 17:125-129.
11. Brydak L.B., R. Rokicka-Milewska, M. Machala, et al. 1998. Efficacy of subunit trivalent influenza vaccine in previously vaccinated children suffering from hemophilia. Clin. Microbiol. Infect. 4:589-593.
12. Brydak L.B., M. Roszkowska-Blaim, M. Machala, et al. 2000. Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases. Vaccine 18:3280-3286.
13. Brydak L.B., M. Roszkowska-Blaim, M. Machala, et al. 2001. Immunological response to influenza vaccination in children with renal failure. Nephrol. Dial. Transplant. 16:643-644.
14. Centers for Disease Control and Prevention. 2003. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 52(No. RR-8).
15. Centers for Disease Control and Prevention (CDC). 2003. Severe morbidity and mortality associated with influenza in children and young adults-Michigan, 2003. MMWR 52):837-840.
16. Commission of the European Communities. 1992. The Rules Governing Medicinal Products in the European Community. Commission of the European Communities 3,2:93-98.
17. Committee for Proprietary Medicinal Products (CPMP). 1997. Note for guidance on harmonisation of requirements for influenza vaccines (revision). CPMP/BWP/214/96.
18. WHO Collaborating Centers for Reference and Research on Influenza. 1982. Concepts and Procedures for Laboratory-Based Influenza Surveillance. U.S. Department of Health and Human Services, Public Health Service, Centers for Diseases Control.
19. Demicheli, V., T. Jefferson, D. Rivetti, et al. 2000. Prevention and early treatment of influenza in healthy adults. Vaccine 18:957-1030.
20. Douglas, A.R. 1993. Assay of neuraminidase (NA) activity and neuraminidase inhibition test. Report of the WHO International Collaborative Center for Reference and Research on the Influenza Virus at Mill Hill. London: National Institute for Medical Research.
21. Ellis, S.E., C.S. Coffey, E.F. Mitchel, Jr., et al. 2003. Influenza- and respiratory syncytial virus-associated morbidity and mortality in the nursing home population. J. Am. Geriatr. Soc. 51:761-767.
22. Ghendon, Y. 1990. The immune response to influenza vaccines. Acta Virol. 34:295-304.
23. Goddard, N.L., C.A. Joseph, J.M. Watson, et al. 2003. Three years of low influenza activity-no reason for complacency. Commun. Dis. Public Health 6:128-132.
24. Johansson, B.E., T.M. Moran, and E.D. Kilbourne. 1987. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc. Natl. Acad. Sci. USA 84:6869-6873.
25. Kilbourne, E.D. 1976. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J. Infect. Dis. 134:384-394.
26. Kilbourne, E.D., U. Christenson, and M. Sande. 1968. Antibody response in man to influenza virus neuraminidase following influenza. J. Virol. 2:761-762.
27. Monto, A.S., J.S. Koopman, and I.M. Longini Jr. 1985. Tecumseh study of illness: XII. Influenza infection and disease, 1976-1981. Am. J. Epidemiol. 121:811-822.
28. Neuzil, K.M., C. Hohlbein, Y.W. Zhu. 2002. Illness among schoolchildren during influenza season-effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch. Pediatr. Adol. Med. 156:986-991.
29. Neuzil, K.M., C. Maynard, M.R. Griffin, et al. 2003. Winter respiratory viruses and health care use: a population-based study in the northwest United States. Clin. Infect. Dis. 37:201-207.
30. Nichol, K.L. 2001. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch. Intern. Med. 161:749-759.
31. Nichol, K.L. 2003. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21:1769-1775.
32. Nichol, K.L., A. Lind, K.L. Margolis, et al. 1995. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med. 5,333:889-893.
33. Nicholson, K.G. 1996. Socioeconomics of influenza and influenza vaccination in Europe. PharmacoEconomics. 9(suppl 3):75-78.
34. Paget, W.J., T.J. Meerhoff, N.L. Goddard, et al. 2002. Mild to moderate influenza activity in Europe and the detection of novel A(H1N2) and B viruses during the winter of 2001-02. Eur. Commun. Dis. Bull. 7:147-157.
35. Palache, A.M. 1997. Influenza vaccines: a reappraisal of their use. Drugs 54:841-856.
36. Rokicka-Milewska, R., L.B. Brydak, M. Machala, et al. 2000. Antibody response to influenza vaccine in children with severe and mild hemophila. Int. J. Pediatr. Hematol. Oncol. 7:21-27.
37. Van Essen, G.A., A.M. Palache, E. Forleo, et al. 2003. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 21:1780-1785.
38. Wilde, J.A., J.A. McMillan, J. Serwint, et al. 1999. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 281:908-913.